Use of slaphylococcus aureus enterotoxins in preparing drugs for treating or preventing A1DS

A technology of staphylococcus enterica and staphylococcus, which is applied in antiviral agents, pharmaceutical formulations, and medical preparations containing active ingredients, etc., can solve the problems of high price and patient burden, and achieve the effect of increasing the ratio and improving the antiviral ability.

Inactive Publication Date: 2004-07-07
SHENYANG XIEHE GRP LTD
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] With the development of society, AIDS is threatening people's health more and more seriously, especially in my country, the incidence of AIDS is showing an upward trend; from the current world perspective, most of the drugs used to treat AIDS are artificially synthesized chemical substances. And it is expensive, causing a heavy burden to the society and patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] The cultivation of staphylococcus aureus and the separation method of fermentation broth:

[0030] Generally speaking, the steps of separating and purifying enterotoxin are relatively complicated, and its preparation is carried out according to the following steps:

[0031] 1) Recovery of strains: using A, B, and C that produce Staphylococcus aureus enterotoxin 1 、C 2 、C 3 The standard strains of , D and TSST-1 were cultured and revived on LB agar surface, and cultured at 37°C for 20 hours. The formula of LB medium was as follows:

[0032] 0.5-1% tryptone, 0.1-0.5% yeast extract, 0.1-0.5% sodium chloride;

[0033] 2) Inoculation: Inoculate aseptically, inoculate the resuscitated bacteria into 300ml LB liquid medium, shake at 37°C for 20 hours, incubate at 4°C as seed liquid, and store for no more than 48 hours;

[0034] 3) Expanded cultivation: prepare 5 liters of LB culture solution in the bacterial fermentation tank culture solution, autoclave at 121° C. for 15 mi...

Embodiment 2

[0037] Purification of Enterotoxin A from Staphylococcus aureus

[0038] 1) Molecular interception and concentration; the collected supernatant is concentrated by ultrafiltration with a 10KD membrane, and washed and balanced with 0.008-0.15M sodium phosphate buffer (PH6.0), and finally 15-25ml of this concentrated solution is collected, and each milliliter contains intestinal Toxin 5~10mg;

[0039] 2) Ion exchange separation: Equilibrate the carboxymethyl cellulose column with 10mM sodium phosphate buffer (PH6.0), pump the above-mentioned concentrated solution into the column, and use 8mM sodium phosphate buffer (PH6.0) to remove impurities that cannot be adsorbed. Remove the protein, then use 0.01M and 0.05M sodium phosphate buffer (pH6.0) to gradiently elute the enterotoxin, adjust the pH value of the eluted enterotoxin solution to 5.7, and separate again with a hydroxyapatite column, Wash the equilibrated apatite (1g / 3.5) column with 8mM sodium phosphate buffer (PH5.7), an...

Embodiment 3

[0042] Purification of Enterotoxin B from Staphylococcus aureus

[0043] 1) Molecular cut-off concentration; the collected supernatant is concentrated by membrane ultrafiltration with a molecular weight of 10KD, and washed and balanced with 0.008-0.15M sodium phosphate buffer (PH6.0-6.2), and finally 50-100ml of concentrated solution is collected. Contains enterotoxin 5~10mg;

[0044] 2) Ion exchange separation: Equilibrate the carboxymethyl cellulose column with 10mM sodium phosphate buffer (PH6.2), pump the above concentrated solution into the column, and use 10mM sodium phosphate buffer (PH6.2) to remove impurities that cannot be adsorbed. Protein removal, and then use 0.02M and 0.07M sodium phosphate buffer (PH6.0~6.8) to gradiently elute enterotoxin, and the eluate is ultrafiltered with a 10KD membrane to concentrate enterotoxin, and use 1M inorganic salt (for example: phosphoric acid Salt) in 0.5M sodium phosphate buffer (PH6.8) equilibrium;

[0045] 3) Molecular sieve...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An application of staphylococcus aureus enterotoxin in preparing the medicines for preventing and treating AIDS is disclosed. Said enterotoxin may be SEA, SEB, SEC1, SEC2, and SED. Its advantages are low dosage and high curative effect.

Description

technical field [0001] The invention relates to a drug for treating AIDS, in particular to the application of Staphylococcus aureus enterotoxin in the preparation of drugs for treating or preventing AIDS. Background technique [0002] AIDS is caused by human immunodeficiency virus (HIV) infection, which leads to the partial or complete loss of the immune function of the infected person, followed by opportunistic infections, tumors and other diseases. After HIV invades the human body, it mainly attacks a virus with CD 4 Lymphocytes (T 4 Lymphocytes), this cell is the basic component of the immune system, HIV through a large number of continuous replication and release, leading to T 4 A large number of lymphocytes die, making T in the human body 4 Lymphocytes are significantly reduced, and the immune function of infected patients is severely damaged, resulting in immune deficiency; clinical manifestations are various opportunistic infections and tumors. Once HIV enters the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P31/18
Inventor 陈巨余
Owner SHENYANG XIEHE GRP LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap